213 related articles for article (PubMed ID: 34923608)
21. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
22. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
23. Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities.
Muhsen K; Maimon N; Mizrahi AY; Boltyansky B; Bodenheimer O; Diamant ZH; Gaon L; Cohen D; Dagan R
JAMA Intern Med; 2022 Aug; 182(8):859-867. PubMed ID: 35737368
[TBL] [Abstract][Full Text] [Related]
24. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
[TBL] [Abstract][Full Text] [Related]
25. Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents.
Dyer AH; Noonan C; McElheron M; Batten I; Reddy C; Connolly E; Pierpoint R; Murray C; Leonard A; Higgins C; Reilly P; Boran G; Phelan T; McCormack W; O'Neill D; Fallon A; Brady G; O'Farrelly C; Bourke NM; Kennelly SP
J Am Med Dir Assoc; 2022 Mar; 23(3):434-439. PubMed ID: 35219507
[TBL] [Abstract][Full Text] [Related]
26. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
[TBL] [Abstract][Full Text] [Related]
27. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
[TBL] [Abstract][Full Text] [Related]
28. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
29. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
31. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
Tanaka H; Mukai J; Kushibiki K; Mizushima S; Maeda K; Fujimoto Y; Sawada R; Oda M; Okuda H; Yamaki M; Hashiguchi S; Kawai I; Kawaguchi I; Masuda N; Matsushita H
Vaccine; 2023 Jan; 41(2):365-371. PubMed ID: 36460533
[TBL] [Abstract][Full Text] [Related]
32. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
33. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
Kanji JN; Bailey A; Fenton J; Ling SH; Rivera R; Plitt S; Sligl WI; Taylor S; Turnbull L; Tipples G; Charlton CL
Vaccine; 2021 Sep; 39(39):5563-5570. PubMed ID: 34454782
[TBL] [Abstract][Full Text] [Related]
34. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
35. Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273.
Ailsworth SM; Keshavarz B; Richards NE; Workman LJ; Murphy DD; Nelson MR; Platts-Mills TAE; Wilson JM
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):67-73. PubMed ID: 36241020
[TBL] [Abstract][Full Text] [Related]
36. Humoral immunity induced by mRNA COVID-19 vaccines in Nursing Home Residents previously infected with SARS-CoV-2.
Fedele G; Palmieri A; Damiano C; Di Lonardo A; Leone P; Schiavoni I; Trevisan C; Abbatecola AM; Cafariello C; Malara A; Minchella P; Panduri G; Antonelli Incalzi R; Palamara AT; Stefanelli P; Onder G;
Aging Clin Exp Res; 2022 Oct; 34(10):2577-2584. PubMed ID: 36127623
[TBL] [Abstract][Full Text] [Related]
37. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
38. Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly.
Dalla Gasperina D; Veronesi G; Castelletti CM; Varchetta S; Ottolini S; Mele D; Ferrari G; Shaik AKB; Celesti F; Dentali F; Accolla RS; Forlani G
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762029
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.
Erdoğan AP; Ekinci F; Akçalı S; Göksel G
J Infect Chemother; 2022 Sep; 28(9):1310-1316. PubMed ID: 35701330
[TBL] [Abstract][Full Text] [Related]
40. Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities.
Causa R; Almagro-Nievas D; Rivera-Izquierdo M; Benítez-Muñoz N; López-Hernández B; García-García F; Alvarez-Estévez M; Soto-Pérez MO; Bermúdez-Tamayo C
Gerontology; 2022; 68(8):910-916. PubMed ID: 34758461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
